title: Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.
abstract: Several classes of antidiabetic agents have been introduced into the market place over the past dozen years. As our understanding of the underlying pathophysiology of type 2 diabetes has advanced, attempts have been made to address these defects specifically. This brief review focuses on our experience with two such pharmacological approaches: (i) a synthetic amylin analog addressing amylin deficiency; and (ii) a dopaminergic agonist, focused on enhancing the lowered dopaminergic tone in patients with type 2 diabetes. Importantly, the use of these agents is not associated with hypoglycemia or weight gain.
authors: Grunberger Diabetes Institute, Bloomfield Hills, MI 48302, USA. grunberger@gdi-pc.com
authors: George
authors: G
authors: Grunberger
mesh_terms: D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007003:Hypoglycemia / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D001971:Bromocriptine; C105254:pramlintide